Browsing by Author "Yildirim S.S."

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
    (Taylor and Francis Ltd., 2024) Yildirim H.C.; Bayram E.; Chalabiyev E.; Majidova N.; Avci T.; Güzel H.G.; Kapar C.; Uzun M.; Perkin P.; Akgül F.; Yildirim S.S.; Sali S.; Yildiz A.; Kazaz S.N.; Hendem E.; Arcagok M.; Tufan G.; Yildirim U.; Akgul O.F.; Arslan Ç.; Taban H.; Sahin E.; Caglayan M.; Esen R.; Öksüzoğlu B.; Guven D.C.; Kaplan M.A.; Araz M.; Basaran M.; Cubukcu E.; Gokmen E.; Cicin I.; Algin E.; Semiz H.S.; Tural D.; Ozturk B.; Erdogan A.P.; Sari M.; Kara O.; Erman M.
    Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial data is limited and treatment options generally follow those of clear cell RCC. In the literature, there exists a number of studies with sunitinib, cabozantinib, and everolimus, but data on the efficacy of pazopanib are limited. Our aim in this study was to compare the efficacy of pazopanib and sunitinib, in a multicenter retrospective cohort of non-ccRCC patients. Our study included patients diagnosed with non-ccRCC who received pazopanib or sunitinib treatment as first-line therapy from 22 tertiary hospitals. We compared the progression-free survival (PFS), overall survival (OS), and response rates of pazopanib and sunitinib treatments. Additionally, we investigated prognostic factors in non-ccRCC. PFS and response rates of sunitinib and pazopanib were found to be similar, while a numerical difference was observed in OS. Being 65 years and older, being in the intermediate or poor risk group according to the International Metastatic Renal Cell Carcinoma Database Consortium, having liver metastases, presence of a sarcomatoid component, and having de novo metastatic disease were found to be significantly associated with shorter PFS. Pazopanib treatment appears to have similar efficacy in the treatment of non-ccRCC compared to sunitinib. Though randomized controlled trials are lacking and will probably be never be available, we suggest that pazopanib could be a preferred agent like sunitinib and cabozantinib. © 2024 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).